- Home
- ALLR vs VIVS Comparison
ALLR vs VIVS Comparison
Compare ALLR & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- VIVS
- Stock Information
- Founded
- ALLR 2004
- VIVS 2007
- Country
- ALLR United States
- VIVS United States
- Employees
- ALLR N/A
- VIVS N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLR Health Care
- VIVS Health Care
- Exchange
- ALLR Nasdaq
- VIVS Nasdaq
- Market Cap
- ALLR 4.0M
- VIVS 3.6M
- IPO Year
- ALLR N/A
- VIVS N/A
- Fundamental
- Price
- ALLR $0.85
- VIVS $1.84
- Analyst Decision
- ALLR
- VIVS
- Analyst Count
- ALLR 0
- VIVS 0
- Target Price
- ALLR N/A
- VIVS N/A
- AVG Volume (30 Days)
- ALLR 564.1K
- VIVS 71.5K
- Earning Date
- ALLR 08-04-2025
- VIVS 06-13-2025
- Dividend Yield
- ALLR N/A
- VIVS N/A
- EPS Growth
- ALLR N/A
- VIVS N/A
- EPS
- ALLR N/A
- VIVS N/A
- Revenue
- ALLR N/A
- VIVS $144,000.00
- Revenue This Year
- ALLR N/A
- VIVS $59.08
- Revenue Next Year
- ALLR N/A
- VIVS $18.24
- P/E Ratio
- ALLR N/A
- VIVS N/A
- Revenue Growth
- ALLR N/A
- VIVS N/A
- 52 Week Low
- ALLR $0.61
- VIVS $1.56
- 52 Week High
- ALLR $17.35
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- ALLR 39.03
- VIVS N/A
- Support Level
- ALLR $0.78
- VIVS N/A
- Resistance Level
- ALLR $0.93
- VIVS N/A
- Average True Range (ATR)
- ALLR 0.07
- VIVS 0.00
- MACD
- ALLR -0.02
- VIVS 0.00
- Stochastic Oscillator
- ALLR 18.72
- VIVS 0.00
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.